Seventh Framework Programme and European Commission logos

Advancing the development of life-saving drugs for cardiovascular diseases


In this research program we aim to identify and clinically validate targets that are suitable to start pharmaceutical drug screening and further development.

Our specific objectives are as follows:

  • To identify and select candidate CVD drug targets with a strong relevance to clinical phenotypes based on molecular and omics data from three unique large-scale population cohorts.
  • To further characterize available, and develop new in vitro and in vivo mechanistic and efficacy models that enable the monitoring of the biological function of CVD targets.
  • To develop and optimize cutting edge molecular assays to accurately monitor proteins, RNA and metabolites in preclinical and clinical biosamples relevant to CVD.
  • To apply molecular assays to further characterize biosamples of two comprehensive well-annotated human CVD biobanks to investigate and validate the contribution of specific pathways to CVD.
  • To apply the in vitro and in vivo models and human biobanks to select and prioritise CVD targets.
  • To develop and exploit this newly formed pan-European modular pharmaceutical target discovery network in cardiovascular disease.